Antiproliferative activity of dmoPTA–Ru(II) complexes against human solid tumor cells

Rios‐Luci, Carla; León, Leticia G.; Mena-Cruz, Adrián; Pérez-Roth, Eduardo; Lorenzo‐Luis, Pablo; Romerosa, Antonio; Padrón, José M.

doi:10.1016/j.bmcl.2011.05.116

Cited by 26 publications

(35 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Overall, the data show that all complexes induce growth inhibition in all cell lines with GI 50 values in the range 0.8-6.5 μM. 5 This fact supports that the main antiproliferative active site in the bimetallic complexes is the ruthenium atom but the influence of the other metal unit must not be excluded, modulating the antiproliferative activity of the complexes. In fact, the Ru(II) complexes were more active against the breast T-47D and the colon WiDr cells, which were less affected by the exposure to cis-platin.…”

Section: Antiproliferative Activitymentioning

confidence: 63%

“…The results expressed as GI 50 (Table 3) were obtained using the SRB assay 10 after 48 hours of exposure to the drugs. Complexes 1 and 2 are transformed quickly in DMSO-water to provide the complex 5 [RuClCp(HdmoPTA)(PPh 3 )] + while 3 is stable enough over the antiproliferative experiment time. When compared to the reference drug cis-platin, compounds 1-3 showed a superior activity profile.…”

Section: Antiproliferative Activitymentioning

confidence: 99%

“…† CCDC 929129 (2) and 929128 (3). 5 To have more information on the influence of the second metal bonded to the dmoPTA in the chemical properties of the {RuCpCl(dmoPTA)(PPh 3 )}moiety, the new bimetallic complexes [RuClCp(PPh 3 )μ-dmoPTA-1κP:2κ 2 N,N′-MCl 2 ] (M = Co (1), Ni (2) and Zn (3)) were synthesized, containing the simple and more reactive {MCl 2 }-unit. E-mail: romerosa@ual.es b possible to combine the properties of different metal centres such as in [RuClCp(PPh 3 )-μ-dmoPTA-1κP:2κ 2 N,N′-M(acac-κ 2 O,-O′) 2 ] (M = Co, Ni, Zn).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Synthesis and antiproliferative activity of the heterobimetallic complexes [RuClCp(PPh3)-μ-dmoPTA-1κP:2κ2N,N′-MCl2] (M = Co, Ni, Zn; dmoPTA = 3,7-dimethyl-1,3,7-triaza-5-phosphabicyclo[3.3.1]nonane)

et al. 2013

Self Cite

View full text Add to dashboard Cite

The synthesis and characterization of three novel heterobimetallic derivatives of general formula [RuClCp(PPh₃)-μ-dmoPTA-1κP:2κ²N,N'-MCl₂] (M = Co (1), Ni (2) and Zn (3), dmoPTA = 3,7-dimethyl-1,3,7-triaza-5-phosphabicyclo[3.3.1]nonane) are described. The sizes of their diffusing units are in agreement with the solid-state structures of 2 and 3, supporting a similar solid-state structure for complex 1. The diamagnetic ruthenium-zinc derivative 3 was fully characterized in solution at 193 K by NMR. Electrochemical properties of the complexes were investigated by cyclic voltammetry, supporting the influence of the {MCl₂} moiety on the electronic properties of the Ru-unit. For the three complexes the GI₅₀ values were in the range 0.8-6.5 μM and comparable to those of the standard anticancer drug cis-platin in the same cell lines.

show abstract

Section: Antiproliferative Activitymentioning

confidence: 63%

Section: Antiproliferative Activitymentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Synthesis and antiproliferative activity of the heterobimetallic complexes [RuClCp(PPh3)-μ-dmoPTA-1κP:2κ2N,N′-MCl2] (M = Co, Ni, Zn; dmoPTA = 3,7-dimethyl-1,3,7-triaza-5-phosphabicyclo[3.3.1]nonane)

et al. 2013

Self Cite

View full text Add to dashboard Cite

show abstract

“…[33][34][35][36] These complexes can also interact with peptide fragments or proteins. [33][34][35][36] These complexes can also interact with peptide fragments or proteins.…”

Section: Discussionmentioning

confidence: 99%

“…[33][34][35][36][37] The use of NAMI-A provides new perspectives on cancer chemotherapy. [33][34][35][36][37] The use of NAMI-A provides new perspectives on cancer chemotherapy.…”

Section: Introductionmentioning

confidence: 99%

Inhibitory effects of NAMI-A-like ruthenium complexes on prion neuropeptide fibril formation

et al. 2015

View full text Add to dashboard Cite

Prion diseases are a group of infectious and fatal neurodegenerative disorders caused by the conformational conversion of a cellular prion protein (PrP) into its abnormal isoform PrP(Sc). PrP106-126 resembles PrP(Sc) in terms of physicochemical and biological characteristics and is used as a common model for the treatment of prion diseases. Inhibitory effects on fibril formation and neurotoxicity of the prion neuropeptide PrP106-126 have been investigated using metal complexes as potential inhibitors. Nevertheless, the binding mechanism between metal complexes and the peptide remains unclear. The present study is focused on the interaction of PrP106-126 with NAMI-A and NAMI-A-like ruthenium complexes, including KP418, KP1019, and KP1019-2. Results demonstrated that these ruthenium complexes could bind to PrP106-126 in a distinctive binding mode through electrostatic and hydrophobic interactions. NAMI-A-like ruthenium complexes can also effectively inhibit the aggregation and fibril formation of PrP106-126. The complex KP1019 demonstrated the optimal inhibitory ability upon peptide aggregation, and cytotoxicity because of its large aromatic ligand contribution. The studied complexes could also regulate the copper redox chemistry of PrP106-126 and effectually inhibit the formation of reactive oxygen species. Given these findings, ruthenium complexes with relatively low cellular toxicity may be used to develop potential pharmaceutical products against prion diseases.

show abstract

Water‐Soluble Phosphanes Derived from 1,3,5‐Triaza‐7‐phosphaadamantane and Their Reactivity towards Gold(I) Complexes

et al. 2013

View full text Add to dashboard Cite

New water‐soluble phosphanes derived from 1,3,5‐triaza‐7‐phosphaadamantane, namely, [PTA–R]Br (R = –CH2C≡CH, –CH2CONH2, –CH2COOH), are described. Coordination of these phosphanes and their previously reported counterparts (R = –CH2CN, –CH2Ph and –CH2COOMe) to gold(I) salts gives water‐soluble derivatives with chlorido, bromido or pentafluorophenyl coligands. The luminescence properties of all new compounds have been studied in the solid state and compared with the respective free PTA ligands. [PTA–CH2Ph]Br, [PTA–CH2COOMe]Br and [AuBr(PTA–CH2Ph)]Br have also been characterised by X‐ray diffraction analysis. Some of the new gold(I) compounds exhibit strong antiproliferative effects in the human ovarian carcinoma cell line A2780 and its cisplatin‐resistant variant (A2780cisR). A balanced relationship between lipophilicity and hydrophilicity is found in these derivatives, with distribution coefficients (log D7.4) that range from 0.14 to –0.40.

show abstract

Antiproliferative activity of dmoPTA–Ru(II) complexes against human solid tumor cells

Cited by 26 publications

References 28 publications

Synthesis and antiproliferative activity of the heterobimetallic complexes [RuClCp(PPh3)-μ-dmoPTA-1κP:2κ2N,N′-MCl2] (M = Co, Ni, Zn; dmoPTA = 3,7-dimethyl-1,3,7-triaza-5-phosphabicyclo[3.3.1]nonane)

Synthesis and antiproliferative activity of the heterobimetallic complexes [RuClCp(PPh3)-μ-dmoPTA-1κP:2κ2N,N′-MCl2] (M = Co, Ni, Zn; dmoPTA = 3,7-dimethyl-1,3,7-triaza-5-phosphabicyclo[3.3.1]nonane)

Inhibitory effects of NAMI-A-like ruthenium complexes on prion neuropeptide fibril formation

Water‐Soluble Phosphanes Derived from 1,3,5‐Triaza‐7‐phosphaadamantane and Their Reactivity towards Gold(I) Complexes

Contact Info

Product

Resources

About